Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of oral PD-L1 inhibitor INCB086550 in immune checkpoint inhibitor-naive selected solid tumors
2020-000157-27Phase 2Completed
- Sponsor
- Incyte
- Start
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of incb086550 in Nonhematologic neoplasms, sponsored by Incyte. Primary endpoint: Objective response rate. Started Jul 2020; status: completed.
02
Drugs
incb086550
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on 2020-000157-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000157-27.